Pershing Square Capital Management LP has filed a lawsuit in Delaware court seeking a declaratory judgment to confirm that its recent push for a special meeting of Allergan, Inc. (NYSE:AGN) shareholders won’t trigger Allergan’s recently adopted poison pill.
The lawsuit, unveiled Friday, comes after a request Pershing made earlier this month to Allergan, Inc. (NYSE:AGN). The firm seeks confirmation that the company won’t use its poison pill to impede the calling of a special meeting. Pershing wants to call for a special meeting of Allergan shareholders in an effort to unseat six members of the company’s board.
Bonhoeffer Fund's performance update for the month ended July 31, 2022. Q2 2022 hedge fund letters, conferences and more The Bonhoeffer Fund returned 3.5% net of fees in July, for a year-to-date return of -15.8%. Bonhoeffer Fund, LP, is a value-oriented private investment partnership for . . . SORRY! This content is exclusively for Read More
Allergan’s poison pill
In April, Allergan, Inc. (NYSE:AGN) announced that if any “unapproved investor” acquired at least 10% of its stock,